Avidity Biosciences Inc. (RNA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.71 per share a year ago.
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for
Avidity Biosciences (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Avidity Biosciences Zoomed to a 12% Gain This Week
The company's most promising pipeline program can continue unabated.
Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases
Goldman Sachs has initiated coverage on Avidity Biosciences Inc RNA based on multi-blockbuster, first-to-market commercial opportunities for its investigational candidates.
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
However, even with this massive appreciation, Wall Street analysts still see a solid upside in the stock. Based on recent analyst changes, the average price target is $62, implying an upside of 39%.
Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders
Avidity Biosciences, Inc. achieved positive results from phase 1/2 FORTITUDE study, using Del-brax for the treatment of patients with FSHD. Positive results achieved from phase 1/2 EXPLORE44 study, using Del-zota for the treatment of patients with DMD. The Phase 3 HARBOR study, using Del-desiran for the treatment of patients with myotonic dystrophy type 1, was initiated in June 2024.
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.66 per share a year ago.
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.
Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline
Avidity Biosciences specializes in targeted RNA therapeutics using its AOC platform. Their most advanced drug candidate, del-desiran, shows promising results in clinical trials for myotonic DM1. The company has achieved significant milestones, including FDA breakthrough therapy status and positive trial results, increasing the likelihood of FDA approval.
